Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease – Authors’ reply

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	The Lancet Gastroenterology & Hepatology
Vol/bind	8
Udgave nummer	7
Sider (fra-til)	604
Antal sider	1
ISSN	2468-1253
DOI	https://doi.org/10.1016/S2468-1253(23)00155-3
Status	Udgivet - jul. 2023

Dokumenter og links

@article{aec3247fa60a49ea9721c233f1cf0ccf,

title = "Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease – Authors{\textquoteright} reply",

keywords = "Humans, Liver Cirrhosis, Liver Diseases, Rifaximin/therapeutic use",

author = "Mads Israelsen and Nikolaj Torp and Stine Johansen and Maja Thiele and Aleksander Krag",

year = "2023",

month = jul,

doi = "10.1016/S2468-1253(23)00155-3",

language = "English",

volume = "8",

pages = "604",

journal = "The Lancet Gastroenterology & Hepatology",

issn = "2468-1253",

publisher = "Elsevier",

number = "7",

}

TY - JOUR

T1 - Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease – Authors’ reply

AU - Israelsen, Mads

AU - Torp, Nikolaj

AU - Johansen, Stine

AU - Thiele, Maja

AU - Krag, Aleksander

PY - 2023/7

Y1 - 2023/7

KW - Humans

KW - Liver Cirrhosis

KW - Liver Diseases

KW - Rifaximin/therapeutic use

U2 - 10.1016/S2468-1253(23)00155-3

DO - 10.1016/S2468-1253(23)00155-3

M3 - Comment/debate

C2 - 37301207

AN - SCOPUS:85161270883

SN - 2468-1253

VL - 8

SP - 604

JO - The Lancet Gastroenterology & Hepatology

JF - The Lancet Gastroenterology & Hepatology

IS - 7

ER -